Premier Biomedical, Inc.(OTCQB: "BIEI") a biotech research company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer, as well as for fibromyalgia, neuropathy, atherosclerosis and muscular dystrophy, announced today they have released a video titled, "A Scientific Roadmap to Cure Cancer", explaining its extracorporeal (outside the body) treatment in scientific and medical terms. Premier Biomedical intends to develop its proprietary methodology in which the pathologies are eradicated by treating and sequentially dialyzing the patient's bodily fluids extracorporeally to avoid dangerous side effects associated with conventional approaches, such as radiation and chemotherapy. This same process can be used to treat other diseases and viruses by physically removing the pathophysiologic basis of the disease by way of compounds not readily tolerated inside the body.
The video, while intended primarily for viewers from the medical community, conveys in broad terms the science and unique approach Premier Biomedical is taking to combat cancer and other diseases, along with a thorough technical review of the underlying intellectual property: "Sequential Extracorporeal Treatment of Bodily Fluids" (U.S. Patent #9,216,386); "Utilization of Stents for the Treatment of Blood Borne Carcinomas" (U.S. Patent #8,758,287); and, pending intellectual property applications. Click here to view the video.
William A. Hartman, CEO and President of Premier Biomedical, stated that, "I believe that we have a clear roadmap for potentially curing cancer, possibly at any stage, and even after extensive metastasis. This intellectual property supports our on-going experimentation and plans to present our stunning results to the American Association for Cancer Research (AACR) Conference in New Orleans, April 16-20, 2016."
About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans, initially targeting the treatment of cancer. The Company's common stock trades on the Over-The-Counter market under the ticker symbol "BIEI." http://www.premierbiomedicalinc.com/
For more information, visit our website http://www.premierbiomedical.com/
Safe Harbor Notice
Statements made in this news release constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Premier Biomedical makes no guarantee of future performance and actual results could differ materially. Premier Biomedical, Inc. undertakes no obligation to revise or update these.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160208005818/en/